title: [The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer - 229 clinical cases].
abstract: We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.
authors.affiliation: Osaka Cancer Immuno-Chemotherapy Center.
authors.forename: Kana
authors.initials: K
authors.lastname: Nakamura
authors.forename: Sayaka
authors.initials: S
authors.lastname: Hanazawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Takeda
authors.forename: Rumi
authors.initials: R
authors.lastname: Sumiyoshi
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Takeda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeda
mesh_terms: D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007167:Immunotherapy; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D014594:Uterine Neoplasms / Q000276:immunology / Q000628:therapy*